Nanosphere — Investor Presentation (May 2012)
26 slides from Nanosphere's investor presentation, May 8, 2012
Slide 1: Company Overview May 2012
Company Overview \. y,—t—‘“‘i—CSY yF—i“‘(‘iéiY MY © Nanosphere SOS
Slide 2: Forward-Looking Statements
Forward-Looking historical rowth involve implied se forward-looking statements reflect financial these general we competitors relevant when market, payors perform acceptance deceleration terms, believe forward-looking “breakeven of circumstances to and known aby future as the statements and reimburs
Slide 3: Nanosphere: Positioned to Become a Global Leader in Molecular Diagnostics
Nanosphere: diseases Accurate Vascular model Clear Molecular Plavix andpath Positioned rapid and toresults Diagnostics profitability Enteric to Viruses Become warfarin -Disposable $4B &a Multi-dimensional chronic Global (10-15%) test MDx heart Cardiovascular cartridge Leader Cost effective growth ma
Slide 4: Drivers of the MDx Industry
Drivers cost complex of theproblems MDx Industry is effective Decentralization results is driving Complex. . . Disease driving .(from .. . Double-Sample-To- reference labs to hospitals) Product Feature Detection Digit- (10-30 Result targets Plexing per sample) Hospitals Need are taking Hospitals' so
Slide 5: Decentralization Driven by Hospital Labs
Drivenplatforms Decentralization MDx Mainly by in10-15% MDx, the next Hospital $20.6B 3 years$29.3B Labs 5 Note: Represent Growth Based Hospital upon a Faster WallGrowing Labs Street (6,000 research Market in total; than and1,500 Nanosphere Reference currently Labs management offer U.S.MDx) Market e
Slide 6: Untapped Markets Available Five Years Ago
Five YearsUntapped Available screening) 6Ago, Note: Sample-To-Result Based Markets upon Sample-To- WallMDx Street Was Global research Enough Result andToMarket Nanosphere Establish Needed? Leadership management Size MRSA In A estimates. Previously Yes $300MUntapped Sample-to-result Market Five capab
Slide 7: Today, Untapped Markets Need Double-Digit Plexing
Today, market BSI, estimates. Enteric, Sample-To-Result leaderExtended in . . . Available TB,WITH HAI, Untapped Double-Digit-Plexing Meningitis, Markets etc. Ideal will require Global Is Needed aNumber platform To Break Market with Into (i)ofThe sample-to-result “Plex” Untapped Size BSI Markets AND
Slide 8: Blood Stream Infection: Ripe To Become The Next MDx Market
Blood times $19,000 Jun 2008, costly Stream savings 4(3):637-640 U.S. Infection 2-hour passes,(BSI): and turnaround BSIElixhauser, causes Ripe(2-7 To higher Become et dayal,than reduced AHRQ, The all hospitalization Next stay Statistical per Significant patient) Brief an MDx (versus #122, 8% higher
Slide 9: The Untapped BSI Market
The Untapped quarters consumable Cepheid] result, multiplexed has capabilities Biomerieux hadBSI very Market assay will lowApril into sales address wasthe 2010 Attempts due $260M was to: -- "The similar terminated and BSIwill has Dx to address existing Begun consumables in '10 to due market technolo
Slide 10: Competitive Landscape Emerges
Filtering Filter major Respiratory Positioned double-digit-plexed theMDx. Competitive Filter 10 Note: Decentral- Landscape, product, Based to upon NSPH Build NSPH Wall chose 100 Emerges Street Yes BSI Yes research while asDouble theIdaho Market andized Nanosphere chose Leader Installed Respiratory.
Slide 11: BSI Opportunity Similar to MRSA Roll-Out
NSPH's $300M next significant MRSA BSI Opportunity $260M sample-to-result BSIand Market Roll-Out MDx Initial market is Similar Quarterly 11 to CPHD's Placement MRSA 30 (Actual Opportunity ResultsMDx 1Q07) in 30 sample-to-result (Actual Results Unique 4Q11)Feature Ramp-UpMDx Weinbelieve sample-to-res
Slide 12: US Market Opportunity Comparable to MRSA
NSPH's 2009 US Market blood MDx (Surveillance CPHD is $ MRSA CPHD's U.S. Average Consumables Percent Global $BSI 56.9 patients Consumables comparable Market &of Selling $MRSA Diagnostic) 58.9 U.S. tested Market Opportunity $patients MDx Price 60.7 addressable (Surveillance forOUS Per Consumables OUS
Slide 13: Market Cap Surge Similar to CPHD's
NSPH's key <5 cap 1/2/2004 1up 80 1 3600% 1/2/2004 Surge 01/2/2005 0 0600% Announcement In1/2/2005 Placements 1/2/2006 500% 1/2/2006 Market 1/2/2007 IsDate Similar Cap MRSA 1/2/2007 1/2/2008 500% To CPHD's approval 1/2/2008 400% 1/2/2009 Which >$1.4B (1)1/2/2009 Based 1/2/2010 Drove 400% upon 1/2/20
Slide 14: Beyond BSI, A Number of Other Value Drivers
Beyond Positive $0.00 1/3/2012 BSI, C. diff NSPH Approval 1/3/2013 Has A 14 $4.00 Number Approval Of Other Enteric Drivers & Gram Of Value Negative For The $3.50 Remainder Analyst Day Of 2012 Trials2Q $3.00 to 4Q 2Q-4Q 2012 2C19 Drivers Approval of ShareGuidance Price Appreciation NSPH $2.50 $5.00 T
Slide 15: Nanosphere Has a Clear Path to Profitability
Nanosphere Average annual has customer a Clear Path Average to Profitability annual customer Break-even Weighted customer average baseconsumable 141 installed price/test(1) base at end$of 45Q1 15 2012 Note Break-even (1): Includesthreshold weighted- average $80M @of60% U.S.GP sales $70Mprices Clear
Slide 16: Microbiology Menu Drives Revenue per Customer
Microbiology C. 2012) difficile Next In Four Clinical Pipeline Quarter Trials Drives Estimate $40 Nanosphere BSI (mid-point) - Gram to Profitability Negative EstimatedIn Placements Development Regulatory end Status Enteric of Q1 Est.Panel 2013 Annual 16 In Development (1) Microbiology Staph portion
Slide 17: Cardio Diagnostics and Metabolism Menu
Cardio Diagnostics Metabolism revenue per customer PendingProvides $40 $140 Troponin KSignificant $300 In (1)Clinical Not Upside currently Trials Regulatory $30 available Annualized Status on Verigene Est. revenue Annual SPper In Cardiovascular US. cardioDx 17 customer Menu FDA $40 KCE $110 IVDAnnua
Slide 18: Ultra-sensitivity Expands Troponin Medical Utility
Ultra-sensitivity Expands Troponin Medical Utility Current Assays Detect AMI Only Normal Range 18 Source: N Engl J Med 2009; 361:858-67
Slide 19: Ultra-sensitive Troponin Market Opportunity
Ultra-sensitive High test/visit riskxpatient 14.5M Proteins early visitsrule 14.5M Provides out $4.0M 25 Additional $$363M 25 $ 100M Growth OR Risk-based New Opportunity Chronic monitoring Heart cTnI Failure Application 6M patients; Application (US profile only) CHF 42.0M Tests/yr In-patient $25$/Te
Slide 20: Target Customer Focus
Customer Target customers: Focus National number Full-Service of locations US Reference only Labs Regional Reference Labs with Limited Test Menu ~4,500 Labs not Offering MDx 35,000+ Clinics, Physician Offices / Other Laboratories 20
Slide 21: Commercial Traction and Global Expansion
Commercial Respiratory for: most Asian virus Traction countries RUOandGrowing Germany Global direct Expansion Distribution sales are teamUnderway partners distribution focus United partners in infectious States launch Europe France in Asia/Pacific Japan disease Regional & Established cardiovascular
Slide 22: Cartridge Cost Advantages
Cost Advantages mold cavity counts Cartridge for plastic cost parts reductions At scale,underway cartridgeNear cost below Plastic$5 Components per cartridge term andpath pennies to reduce per target substrate Completed from ~ Cartridge $10 per slide Glass to Substrate < $1 per slide 22 Volume drives
Slide 23: Financial Metrics and Leverage
Financial leverage Established to 70%+ in margins Position Investments international 23 Financial for market near Metrics term presence March growth Manufacturing 31, substantially 2012 Cashcritical complete and cash mass equivalents: Established establishedcustomer $31.8M future investment Debt: ba
Slide 24: Consolidated Market Opportunity
Consolidated AMI sensitive rule-out PSAMarket and for recurrent ACSOpportunity risk prostate $ 100M U.S. disease stratification Market $ 20M Opportunity PLUS PLUSIntermediate 5- Immediate 8 Year Horizon Market Market Platform Development Accesscan Conversion do(3-5 all molecular years; of Microbiolo
Slide 25: Investment Opportunity
Investment diseases Thrombophilia markets in andlife Opportunity cardiovascular science Multi-dimensional research, Molecular disease industrial growth isVerigene the fastest Infections applications, System growing Diseases uniquely and Diagnostics biosecurity Vascular meets key Market Plavix 25Trop
Slide 26: Slide 26